...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: News !!!
5
Feb 26, 2018 07:39AM
1
Feb 26, 2018 09:05AM

Feb 26, 2018 09:30AM
5
Feb 26, 2018 09:43AM
2
Feb 26, 2018 10:17AM
2
Feb 26, 2018 10:24AM
4
Feb 26, 2018 10:32AM
3
Feb 26, 2018 11:00AM
2
Feb 26, 2018 11:12AM
3
Feb 26, 2018 12:29PM

Feb 26, 2018 02:00PM
1
Feb 26, 2018 02:04PM

Feb 26, 2018 07:39PM
2
Feb 26, 2018 08:30PM

BDAZ - If, and that's a big if, the results come in close to what Nicholls et al (from slides presented at the Bio CEO Conference last month) reported at a 62% reduction in the group of patients that represent this trial profile then it would be closer to 12 and 4. Note that there was a very small number of patients in that profile in the previous trial. It would be a stretch to mirror those results but why not dream a little.

dyodd

tada

3
Feb 27, 2018 06:58AM
4
Feb 27, 2018 11:59AM
4
Feb 27, 2018 05:31PM
3
Feb 27, 2018 06:53PM
4
Feb 27, 2018 08:44PM
3
Feb 27, 2018 10:48PM
Share
New Message
Please login to post a reply